Monogram (MGRM) | Financial Analysis & Statements
Monogram Technologies Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Gross Profit
0
Operating Income
-3.1M
Net Income
-5.4M
EPS (Diluted)
$-0.16
Balance Sheet Metrics
Total Assets
15.4M
Total Liabilities
3.7M
Shareholders Equity
11.7M
Debt to Equity
0.31
Cash Flow Metrics
Operating Cash Flow
-2.7M
Free Cash Flow
-2.5M
Revenue & Profitability Trend
Monogram Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 365.0K | 0 | 628.2K | 0 |
| Cost of Goods Sold | - | - | 0 | 458.7K | 0 |
| Gross Profit | - | - | 0 | 169.6K | 0 |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 27.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 8.8M | 10.6M | 5.4M | 5.3M | 4.7M |
| Selling, General & Administrative | 6.5M | 7.0M | 5.2M | 5.2M | 2.2M |
| Other Operating Expenses | - | - | -256.0K | - | - |
| Total Operating Expenses | 15.3M | 17.6M | 10.4M | 10.4M | 6.9M |
| Operating Income | -15.3M | -17.3M | -10.4M | -10.3M | -6.9M |
| Operating Margin % | 0.0% | -4,731.0% | 0.0% | -1,635.9% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 526.0K | 434.3K | 98.1K | 26.1K | 131.5K |
| Interest Expense | - | - | - | 21.7K | 54.2K |
| Other Non-Operating Income | -1.5M | 3.1M | -3.4M | -1.6M | -2.3M |
| Pre-tax Income | -16.3M | -13.7M | -13.7M | -11.8M | -9.1M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -16.3M | -13.7M | -13.7M | -11.8M | -9.1M |
| Net Margin % | 0.0% | -3,765.8% | 0.0% | -1,880.6% | 0.0% |
| Key Metrics | |||||
| EBITDA | -14.9M | -19.9M | -6.5M | -8.4M | -6.6M |
| EPS (Basic) | $-0.46 | $-0.61 | $-0.44 | $-0.38 | $-0.29 |
| EPS (Diluted) | $-0.46 | $-0.61 | $-0.44 | $-0.38 | $-0.29 |
| Basic Shares Outstanding | 32571470 | 22409222 | 30917015 | 30917015 | 30917015 |
| Diluted Shares Outstanding | 32571470 | 22409222 | 30917015 | 30917015 | 30917015 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Monogram Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 15.7M | 13.6M | 10.5M | 5.5M | 5.6M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 0 | 365.0K | 0 | - | - |
| Inventory | 288.0K | - | 4.6K | 0 | - |
| Other Current Assets | 305.0K | 354.9K | 380.4K | -11.1K | - |
| Total Current Assets | 16.3M | 14.6M | 11.3M | 6.5M | 6.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.3M | 1.4M | 1.5M | 939.2K | 934.9K |
| Goodwill | 339.0K | 548.8K | 758.8K | 968.8K | 150.0K |
| Intangible Assets | - | - | 1.3M | 968.8K | 150.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 1.5M | 2.0M | 2.4M | 2.2M | 1.7M |
| Total Assets | 17.8M | 16.6M | 13.7M | 8.7M | 8.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.2M | 2.5M | 663.2K | 449.0K | 182.8K |
| Short-term Debt | 138.0K | 128.3K | 118.2K | 92.9K | 57.5K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 7.5M | 4.1M | 2.5M |
| Total Current Liabilities | 1.5M | 2.8M | 9.0M | 5.1M | 3.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 226.0K | 363.7K | 492.0K | 118.6K | 147.9K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.5M | - | 1 | 1 | - |
| Total Non-Current Liabilities | 1.7M | 363.7K | 492.0K | 118.6K | 147.9K |
| Total Liabilities | 3.3M | 3.2M | 9.5M | 5.2M | 3.1M |
| Equity | |||||
| Common Stock | 35.0K | 31.3K | 9.7K | 9.7K | 9.7K |
| Retained Earnings | -68.0M | -51.5M | -37.8M | -24.1M | -12.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 14.5M | 13.4M | 4.1M | 3.5M | 5.0M |
| Key Metrics | |||||
| Total Debt | 364.0K | 492.0K | 610.2K | 211.5K | 205.5K |
| Working Capital | 14.7M | 11.8M | 2.2M | 1.4M | 3.4M |
Balance Sheet Composition
Monogram Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -16.3M | -13.7M | -13.7M | -11.8M | -9.1M |
| Depreciation & Amortization | 430.0K | 412.3K | 386.7K | 322.0K | 95.7K |
| Stock-Based Compensation | 1.2M | 1.6M | 743.3K | 205.6K | 2.2M |
| Working Capital Changes | -924.0K | 1.4M | 425.6K | 294.7K | -832.3K |
| Operating Cash Flow | -14.1M | -10.2M | -12.1M | -11.0M | -7.6M |
| Investing Activities | |||||
| Capital Expenditures | -84.0K | -64.9K | -241.2K | -31.1K | -1.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -84.0K | -64.9K | -241.2K | -31.1K | -1.2M |
| Financing Activities | |||||
| Share Repurchases | -200.0K | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 79.0K |
| Debt Repayment | - | - | - | 0 | -840.0K |
| Financing Cash Flow | 16.1M | 15.5M | 13.6M | 10.1M | 10.0M |
| Free Cash Flow | -14.1M | -13.6M | -8.7M | -10.2M | -6.7M |
| Net Change in Cash | 1.9M | 5.2M | 1.2M | -900.7K | 1.2M |
Cash Flow Trend
Monogram Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-13.04
Forward P/E
-12.50
Price to Book
25.10
PEG Ratio
-0.29
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-228.82%
Return on Assets
-72.90%
Financial Health
Current Ratio
2.16
Debt to Equity
3.44
Beta
0.69
Per Share Data
EPS (TTM)
$-0.54
Book Value per Share
$0.24
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MGRM | 244.2M | -13.04 | 25.10 | -228.82% | 0.00% | 3.44 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Perspective | 514.2M | -3.22 | 1.62 | -41.65% | 0.00% | 1.57 |
| Inogen | 190.4M | -8.14 | 0.99 | -12.43% | -6.52% | 9.09 |
| Nevro | 224.1M | 144.40 | 0.96 | -43.29% | -27.77% | 108.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.






